Literature DB >> 29992292

Chronic Myeloid Leukemia Following Treatment for Primary Neoplasms or Other Medical Conditions.

Lian-He Yang1,2, Pu Su2,3, Catherine Luedke2, Chuanyi Mark Lu4, Abner Louissaint5, Chad M McCall2, Sarah Rapisardo2, Bethany Vallangeon6, Endi Wang2.   

Abstract

OBJECTIVES: Therapy-related chronic myeloid leukemia (CML) has been reported, but its clinical presentation and pathologic features have not yet been well characterized.
METHODS: Twenty-one cases of CML following treatment for primary diseases were collected and retrospectively analyzed.
RESULTS: The clinical presentation, pathologic features, and cytogenetic profile were similar to de novo CML. In particular, those with an isolated Philadelphia chromosome constituted 88.9% of our cases, and additional aberrations characteristic of therapy-related acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) were not identified in this study. The patients responded to imatinib/derivatives and survived with limited follow-up.
CONCLUSIONS: Therapy-related CML has a clinical presentation, pathologic features, and cytogenetic profile akin to de novo CML. Absence of additional significant aberrations seems to suggest a pathogenesis different from therapy-related AML/MDS. Therapy-related CML exhibits a robust therapeutic response to imatinib/derivatives and favorable clinical outcomes similar to de novo CML. © American Society for Clinical Pathology, 2018. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Chronic myeloid leukemia; Cytogenetic profile; Philadelphia chromosome; Therapy-related

Year:  2018        PMID: 29992292     DOI: 10.1093/ajcp/aqy050

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  1 in total

Review 1.  Is There an Entity of Radiation-Induced Chronic Myeloid Leukemia? Report of a Case and Brief Review of the Literature.

Authors:  Isao Miyoshi; Masakazu Mori; Ichiro Yamasaki; Masanori Daibata
Journal:  J Clin Exp Hematop       Date:  2020
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.